1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B.CO
Novo Nordisk A/SDK flagNASDAQ Copenhagen
308.35
DKK
+2.20
- -
1.37TMarket Cap

Total Valuation

Novo Nordisk A/S carries a market capitalization of 1.37T, placing it among publicly traded companies globally. Its enterprise value stands at 1.49T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.37T
Enterprise Value1.49T

Share Statistics

Novo Nordisk A/S currently has 4.42B shares outstanding.

Shares Outstanding4.42B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Novo Nordisk A/S trades at a trailing price-to-earnings ratio of 11.99. The price-to-sales ratio is 4.24, and the price-to-book ratio stands at 6.29.

PE Ratio11.99
PS Ratio4.24
PB Ratio6.29
P/TBV Ratio14.03
P/FCF Ratio6.47
P/OCF Ratio10.59

Enterprise Valuation

On an enterprise value basis, Novo Nordisk A/S trades at an EV/EBITDA multiple of 8.79 and an EV/FCF ratio of 6.87. The EV/Sales ratio of 4.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.47 provides insight into valuation relative to core operating earnings.

EV / Sales4.51
EV / EBITDA8.79
EV / EBIT10.47
EV / FCF6.87

Financial Position

Novo Nordisk A/S maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 285.42 demonstrates strong ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.64
Debt / Equity63.33
Debt / EBITDA0.83
Interest Coverage285.42

Financial Efficiency

Novo Nordisk A/S posts a return on equity of 59.82 and a return on invested capital of 33.40.

Return on Equity (ROE)59.82
Return on Assets (ROA)21.62
Return on Invested Capital (ROIC)33.40
Return on Capital Employed (ROCE)37.19
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.31

Taxes

Over the trailing twelve months, Novo Nordisk A/S has paid 32.31B in income taxes, reflecting an effective tax rate of 21.72.

Income Tax32.31B
Effective Tax Rate21.72

Stock Price Statistics

Novo Nordisk A/S's stock has declined approximately -4.41723% over the past 52 weeks. The 50-day moving average sits at 308.31, while the 200-day moving average is 299.94.

Beta (5Y)N/A
52-Week Price Change-4.41723%
50-Day Moving Average308.31
200-Day Moving Average299.94
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Novo Nordisk A/S generated 329.43B in revenue and converted that into 116.44B in net income, yielding earnings per share of 26.20. EBITDA reached 169.26B, while operating income came in at 142.10B.

Revenue329.43B
Gross Profit265.68B
Operating Income142.10B
Pretax Income148.75B
Net Income116.44B
EBITDA169.26B
EBIT142.10B
Earnings Per Share (EPS)26.20

Balance Sheet

Novo Nordisk A/S holds 44.98B in cash and equivalents against 140.13B in total debt, resulting in a net debt position of 95.65B. Total book value stands at 221.28B, with working capital of -30.39B providing operational flexibility.

Cash & Cash Equivalents44.98B
Total Debt140.13B
Net Debt95.65B
Equity (Book Value)221.28B
Book Value Per Share50.01
Working Capital-30.39B

Cash Flow

Novo Nordisk A/S produced 131.88B in operating cash flow over the past twelve months. After subtracting -84.09B in capital expenditures, free cash flow totaled 47.79B - equivalent to 10.77 per share.

Operating Cash Flow131.88B
Capital Expenditures-84.09B
Free Cash Flow47.79B
FCF Per Share10.77

Margins

Novo Nordisk A/S operates with a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

Gross Margin80.65
Operating Margin43.13
Pretax Margin45.15
Profit Margin35.35
EBITDA Margin51.38

Dividends & Yields

The company's payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share11.71
Dividend YieldN/A
Payout Ratio44.64
Shareholder Yield1.60
FCF Yield15.45

Stock Splits

Novo Nordisk A/S's most recent stock split took place on September 13, 2023 with a 1:2 split ratio.

Last Split Date9/13/2023
Split Ratio1:2

Scores

Novo Nordisk A/S posts an Altman Z-Score of 4.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.51